Schizophrenia drug AbbVie picked up in $9 billion acquisition fails in key trials

Taking stock of the drug industry, from the lab to the medicine chest

November 11, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

AbbVie STAT+ | Schizophrenia drug AbbVie picked up in $9 billion acquisition fails in key trials AbbVie's treatment, emraclidine, which it got the drug through its $9 billion acquisition of Cerevel Therapeutics, failed to significantly help patients. By Elaine Chen STAT+ | What the Trump administration could mean for the health care industry, from hospitals to pharma Health care companies hope for lower taxes, but could face challenges like reduced ACA subsidies and instability at the FDA. By Rachel Cohrs Zhang, Bob Herman, and Tara Bannow Opinion: A new Trump administration will further loosen already-lax rules on supplements In the absence of meaningful regulation from the FDA, the supplement industry will no doubt take RFK Jr.'s stance as a free pass. By S. Bryn Austin and Amanda Raffoul Win McNamee/Getty Images STAT+ | Biotech analyst Brian Skorney and CEO Daphne Zohar weigh in on election results A Baird analyst and longtime biotech executive speak with Readout LOUD hosts about how a Trump presidency could affect the FDA and the biotech industry. By STAT Staff

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser